To investigate if combination therapy targeting EGFR and BCL6 would be more effective in killing cancer cells than monotherapy we treated all three cell lines with gefitinib and FX1, alone or in combination, and evaluated survival using clonogenic assay. The gene discussed is BCL6; the disease is cancer.